Table 5: Clinical effects of the combination therapy with ETV plus BSF.

GroupCaseSex (F/M)Age (years) Rates of virological response (%)Rates of HBsAg decline ≥ 10% (%)

T1-Group1814/446.0 (36.5–49.5)94.466.7
T2-Group75/232.0 (29.0–36.0)/57.1
C1-Group1412/243.0 (37.5–49.5)85.750.0
C2-Group1716/132.0 (27.0–42.0)/52.9